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may frequently represent unrecognised outbreaks
(Table 1).
Home-made food was the most important
source of S. Enteritidis infection in this region,
being implicated in 22 (81%) outbreaks and 134
(81.7%) sporadic infections. This rate is higher
than that in some other reports [2,5]. If imperfect
practice in kitchens has contributed to the striking
increase in S. Enteritidis food poisoning in Bosnia
and Herzegovina, this may be evidence that
standards have declined in recent years, i.e., the
post-war period.
For outbreaks in which the implicated food was
investigated bacteriologically, and in those cases
where epidemiological information regarding the
suspected food was recorded, the main sources of
infection were eggs and food containing eggs
(33%), milk and milk products (22%), and
minced beef (18%). Although this supports pre-
vious findings that eggs and egg products are the
commonest vehicles of S. Enteritidis transmission
[2,4], the large proportion of cases involving raw
milk (22%) suggests that cattle from rural areas
may represent an important source of infection.
However, because of limited resources, food
samples were examined from only five (19%)
S. Enteritidis outbreaks during this 3-year period.
Although the surveillance system for the sources
of S. Enteritidis infections in this region is inad-
equate, this is also a problem in many other
countries [1,2]. Medical staff in general practice
should be strongly encouraged to report suspec-
ted cases to local public health authorities, and
consistent criteria should be developed for their
investigation.
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ABSTRACT
Among shigellas isolated from patients in Eng-
land and Wales in 2002, 10% of subgroups A, B
and C, and 13% of subgroup D (Shigella sonnei),
were resistant to nalidixic acid. As a consequence,
should antimicrobial therapy be indicated, the
efficacy of nalidixic acid as the preferred treat-
ment for children with bacillary dysentery has
been jeopardised.
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The normal presentation of bacillary dysentery
caused by Shigella isolates of subgroups A, B, C
(Shigella dysenteriae, S. flexneri, S. boydii) and D
(S. sonnei) is that of mild-to-moderate gastroen-
teritis. The disease is self-limiting, and the pri-
mary therapy is oral rehydration. However,
symptoms can be severe in the very young, the
very old, the malnourished and patients with
other underlying diseases [1]. In such cases,
administration of an effective antimicrobial agent
should commence as soon as the clinical diagnosis
is made. Ampicillin was the drug of choice until
the mid-1980s [2], but this agent was compro-
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mised by the widespread emergence of ampicil-
lin-resistant strains [3] and was replaced by
co-trimoxazole (trimethoprim–sulphamethoxazole)
and nalidixic acid [4]. More recently, the Ameri-
can Public Health Association has recommended
that, should antibiotic therapy be indicated for
cases of acute shigellosis, oral co-trimoxazole,
ciprofloxacin or ofloxacin should be used for
treating adults, while oral co-trimoxazole, nali-
dixic acid or parenteral ceftriaxone should be
used for treating children [5].
The Laboratory of Enteric Pathogens of the
Health Protection Agency (London, UK) is the
national reference centre for Shigella isolates from
patients in England and Wales. Isolates are
serotyped and tested for resistance to a range of
therapeutic antimicrobial agents at the following
levels (mg ⁄L): ampicillin, 8; ceftriaxone, 1; trim-
ethoprim, 2; nalidixic acid, 16; ciprofloxacin, 0.125
(= CpL) and 1.0 (= CpH) [6]. In 1998, following a
comparative study of results with isolates
received in the period 1978–1983, a substantive
increase in the incidence of resistance to ampicil-
lin and trimethoprim in isolates of subgroups A, B
and C in the period 1995–1996 was reported [7].
Furthermore, c. 50% of S. sonnei (subgroup D)
isolates were resistant to at least one of these
antimicrobial agents, with 15% being resistant to
both. In contrast, the incidence of resistance
to nalidixic acid was low (0.5% for subgroups
A, B and C, and 0.6% for subgroup D). High-
level (clinical) resistance to ciprofloxacin
(MIC ‡ 2 mg ⁄L) was not detected. Based on these
results, it was suggested that, if antimicrobial
therapy was indicated, the best options would be
nalidixic acid for children and a fluoroquinolone,
such as ciprofloxacin or ofloxacin, for adults [7].
The present report documents the incidence of
resistance to key therapeutic antimicrobial agents
in isolates of subgroups A, B, C and D from
patients in England and Wales in 2002.
In total, 912 isolates were studied, comprising
470 (52%) isolates of subgroups A (34), B (372)
and C (64), and 442 (48%) isolates of subgroup D.
In comparison to data from 1995–1996, the inci-
dence of resistance to ampicillin had fallen in all
subgroups, although a substantial proportion
remained resistant (Table 1). In contrast, resist-
ance to trimethoprim had increased by 9% in
subgroups A, B and C, and by 35% in subgroup
D, to the extent that > 70% of all isolates were
resistant. The most dramatic increase in resistance
was observed in relation to nalidixic acid, with a
20-fold increase in resistance in subgroups A, B
and C, and a 25-fold increase in subgroup D
(Table 1). Furthermore, 14% of 77 S. sonnei iso-
lates with resistance to nalidixic acid were from
children aged < 10 years. Resistance to ceftriaxone
was not detected in isolates of any subgroup.
These findings suggest that the efficacy of
nalidixic acid as a preferred drug for the treat-
ment of acute shigellosis in children in England
and Wales has been jeopardised. Most (> 70%)
patients infected with subgroups A, B and C had
a history of recent foreign travel to developing
countries. Nalidixic acid is used for prophylaxis
in many developing countries, and it is possible
that such usage has encouraged the development
of resistance to this antimicrobial agent. However,
the incidence of resistance to nalidixic acid has
also increased 25-fold in isolates of subgroup D
which, in > 50% of cases, were from patients who
had not travelled abroad. Thus, the development
of resistance to nalidixic acid cannot result
entirely from the imprudent use of this antimi-
crobial agent in developing countries.
All isolates of Shigella spp. with resistance to
nalidixic acid also exhibited decreased suscepti-
bility to ciprofloxacin (MIC 0.25–1.0 mg ⁄L),
although clinically significant resistance (MIC
‡ 2 mg ⁄L) was not detected. Therefore, fluoroqu-
inolone antibiotics, such as ciprofloxacin, may still
be effective for the treatment of acute shigellosis
in adults. However, physicians should be aware
that treatment failures caused by strains with
decreased susceptibility to ciprofloxacin have
been reported for other enteric pathogens [8].
All isolates were sensitive to ceftriaxone in the
Table 1. Comparison of resistance (%) to therapeutic
antimicrobial agents in isolates of Shigella dysenteriae,
S. flexneri, S. boydii (subgroups A, B and C) and S. sonnei
(subgroup D) from patients in England and Wales in 1995–
1996 and 2002
Antimicrobial
Subgroups A, B and C
S. dysenteriae, S. flexneri









Ampicillin 65 57 42 31
Trimethoprim 64 73 53 88
Nalidixic acida 0.5 10 0.5 13
Ceftriaxone NT 0 NT 0
NT, not tested.
aAll isolates resistant to nalidixic acid at 16 mg ⁄L also exhibited decreased
susceptibility to ciprofloxacin (MIC 0.25–1.0 mg ⁄L). No isolate had a ciprofloxacin
MIC > 1.0 mg ⁄L (= CpH).
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present investigation, and parenteral treatment
with ceftriaxone has been suggested for children
with shigellosis [5], although reservations have
been expressed regarding both the cost of this
antibiotic and the lack of an oral formulation [4].
Overall, these results demonstrated that the
choice of an antimicrobial agent for the first-line
treatment of shigellosis in England and Wales is
becoming increasingly limited. Because of the
increasing incidence of resistance to nalidixic
acid, it is recommended strongly that isolates
from children aged < 10 years should be tested for
resistance before treatment is commenced. This
recommendation is in line with information
received from other countries, where in some
instances nalidixic acid has now been abandoned
as a therapeutic option for the treatment of acute
shigellosis.
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